Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) FCF Margin (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed FCF Margin for 7 consecutive years, with 2329.37% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 148112.0% to 2329.37% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 597.65% through Dec 2025, down 15718.0% year-over-year, with the annual reading at 597.64% for FY2025, 15717.0% down from the prior year.
  • FCF Margin for Q4 2025 was 2329.37% at Kymera Therapeutics, down from 987.37% in the prior quarter.
  • The five-year high for FCF Margin was 7.48% in Q4 2023, with the low at 2329.37% in Q4 2025.
  • Average FCF Margin over 5 years is 539.17%, with a median of 366.05% recorded in 2022.
  • Peak annual rise in FCF Margin hit 34919bps in 2025, while the deepest fall reached -148112bps in 2025.
  • Over 5 years, FCF Margin stood at 254.36% in 2021, then rose by 3bps to 247.28% in 2022, then soared by 97bps to 7.48% in 2023, then crashed by -11246bps to 848.26% in 2024, then crashed by -175bps to 2329.37% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 2329.37%, 987.37%, and 527.88% for Q4 2025, Q3 2025, and Q2 2025 respectively.